Welcome to our dedicated page for Herbalife SEC filings (Ticker: HLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform. As a foreign-incorporated issuer trading on the New York Stock Exchange, Herbalife files periodic and current reports that give detailed insight into its operations, financial condition, risks and governance.
Herbalife’s SEC filings include current reports on Form 8-K, which the company uses to announce material events such as the release of quarterly financial results and related investor presentations. For example, recent 8-K filings reference earnings press releases for the second and third quarters and note the availability of investor slides used during earnings conference calls.
In addition to 8-Ks, investors can review Herbalife’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available on this page) for comprehensive discussions of net sales, adjusted EBITDA, regional performance, capital structure, and detailed risk factors. These reports also describe topics such as the company’s direct-selling model, international operations, exposure to foreign exchange and tariffs, and legal and regulatory matters, including references to a Consent Order with the U.S. Federal Trade Commission.
Users interested in governance and executive matters can consult proxy statements and, where applicable, Form 4 insider transaction reports to understand equity ownership and trading by directors and officers. Together, these filings form the official regulatory record of Herbalife’s activities and obligations as a public company.
On Stock Titan, each filing is accompanied by AI-powered summaries that highlight key points, explain technical language and help readers quickly understand the implications of lengthy documents such as 10-Ks and 10-Qs. Real-time updates from EDGAR ensure that new Herbalife filings, including earnings-related 8-Ks and other disclosures, appear here promptly with concise, investor-friendly explanations.
LEVY ROBERT reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. reported that President Robert Levy received a grant of 33,301 stock appreciation rights (SARs) on February 25, 2026 under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These derivative awards were granted at a price of $0.00 per right as part of his compensation.
The SARs will vest in three equal installments, with one-third vesting on each of February 25, 2027, February 25, 2028, and February 25, 2029, subject to his continued service through each vesting date. Following this grant, he directly holds 33,301 SARs.
Lamberti Frank reported acquisition or exercise transactions in this Form 4 filing.
Herbalife Ltd. Chief Commercial Officer Frank Lamberti received a grant of 40,437 stock appreciation rights (SARs) on February 25, 2026 under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These SARs were awarded at a price of $0.00 per right.
The SARs vest in three equal installments, with one-third vesting on February 25, 2027, one-third on February 25, 2028, and the final one-third on February 25, 2029, subject to Mr. Lamberti’s continued service through each vesting date. Following this grant, he holds 40,437 SARs directly.
JOHNSON MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. Executive Chairman Michael Johnson reported equity awards rather than open-market trades. On February 25, 2026, he was granted 399,619 stock appreciation rights at
Both the RSUs and SARs were granted under the company’s stock incentive plan and vest in two equal installments: 50% on
Hicks Troy reported acquisition or exercise transactions in this Form 4 filing.
Herbalife Ltd.'s Chief Operating Officer, Troy Hicks, received a grant of 33,301 stock appreciation rights (SARs) on February 25, 2026. These SARs were issued at a price of $0.00 per right and increase in value if the company’s stock price rises.
The award was granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. The SARs will vest in three equal installments on February 25, 2027, February 25, 2028, and February 25, 2029, as long as Hicks continues in service through each vesting date.
Gratziani Stephan Paulo reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. Chief Executive Officer Stephan Paulo Gratziani reported receiving a grant of 215,033 stock appreciation rights on February 25, 2026. These rights were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan as equity-based compensation.
The stock appreciation rights will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, and each installment is subject to his continued service with the company through the applicable vesting date.
DeSimone John reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. Chief Financial Officer John DeSimone received a grant of 45,195 stock appreciation rights under the Amended and Restated 2023 Stock Incentive Plan. These rights were granted at a price of $0.00 per right and will vest in three equal installments on February 25 of 2027, 2028, and 2029, contingent on his continued service with the company.
Wang Henry C reported acquisition or exercise transactions in this Form 4 filing.
HERBALIFE LTD. Chief Legal Officer Henry C. Wang received a grant of 33,301 stock appreciation rights under the company’s Amended and Restated 2023 Stock Incentive Plan. These SARs vest in three equal installments on February 25, 2027, 2028, and 2029, conditioned on continued service.
HERBALIFE LTD. Chief Executive Officer Stephan Paulo Gratziani reported a tax-related share disposition. On February 16, 2026, 3,664 shares of common stock were withheld at
HERBALIFE LTD. Chief Financial Officer John DeSimone reported a tax-withholding share disposition related to vested equity awards. On this Form 4, 17,382 shares of common stock were withheld at
Herbalife Ltd. reported modest growth for Q4 and full-year 2025 and outlined 2026 guidance. Fourth-quarter net sales were $1.283 billion, up 6.3% year-over-year, with net income of $85.4 million and diluted EPS of $0.81. Full-year 2025 net sales reached $5.0375 billion, up 0.9%, and net income was $228.3 million, or $2.20 per diluted share. Adjusted EBITDA was $657.6 million with a 13.1% margin, an improvement versus 2024, and operating cash flow was $333.3 million. The company ended 2025 with a total leverage ratio of 2.8x and an undrawn revolving credit facility. Herbalife expects 2026 net sales to grow 1.0%–6.0% and adjusted EBITDA of $670–$710 million. In a notable strategic move, Cristiano Ronaldo invested $7.5 million for a 10% equity interest in Pro2col Software, Herbalife’s personalized health and wellness technology platform, and agreed to provide services and sponsorship rights.